7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet

Br J Nutr. 2018 Oct;120(7):751-762. doi: 10.1017/S0007114518001824. Epub 2018 Aug 14.

Abstract

7-Hydroxymatairesinol (7-HMR) is a plant lignan abundant in various concentrations in plant foods. The objective of this study was to test HMRLignan™, a purified form of 7-HMR, and the corresponding Picea abies extract (total extract P. abies; TEP) as dietary supplements on a background of a high-fat diet (HFD)-induced metabolic syndrome in mice and in the 3T3-L1 adipogenesis model. Mice, 3 weeks old, were fed a HFD for 60 d. Subgroups were treated with 3 mg/kg body weight 7-HMR (HMRLignan™) or 10 mg/kg body weight TEP by oral administration. 7-HMR and TEP limited the increase in body weight (-11 and -13 %) and fat mass (-11 and -18 %) in the HFD-fed mice. Epididymal adipocytes were 19 and -12 % smaller and the liver was less steatotic (-62 and -65 %). Serum lipids decreased in TEP-treated mice (-11 % cholesterol, -23 % LDL and -15 % TAG) and sugar metabolism was ameliorated by both lignan preparations, as shown by a more than 70 % decrease in insulin secretion and insulin resistance. The expression of several metabolic genes was modulated by the HFD with an effect that was reversed by lignan. In 3T3-L1 cells, the 7-HMR metabolites enterolactone (ENL) and enterodiol (END) showed a 40 % inhibition of cell differentiation accompanied by the inhibited expression of the adipogenic genes PPARγ, C/EBPα and aP2. Furthermore, END and ENL caused a 10 % reduction in TAG uptake in HEPA 1-6 hepatoma cells. In conclusion, 7-HMR and TEP reduce metabolic imbalances typical of the metabolic syndrome and obesity in male mice, whereas their metabolites inhibit adipogenesis and lipid uptake in vitro.

Keywords: 7-HMR 7-hydroxymatairesinol; DMSO dimethylsulfoxide; END enterodiol; ENL enterolactone; HFD high-fat diet; LFD low-fat diet; PA palmitic acid; TEP total Picea abies extract; TFEB transcription factor EB; 7-Hydroxymatairesinol; Adipocyte differentiation; Adipose deposition; Lignan; Metabolism; Obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • 4-Butyrolactone / analogs & derivatives
  • 4-Butyrolactone / pharmacology
  • 4-Butyrolactone / therapeutic use
  • Adipogenesis / drug effects
  • Adipogenesis / genetics
  • Adipose Tissue / cytology
  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Animals
  • Anti-Obesity Agents / pharmacology
  • Anti-Obesity Agents / therapeutic use
  • Blood Glucose / metabolism*
  • Body Weight / drug effects*
  • Diet, High-Fat*
  • Dietary Supplements
  • Fatty Liver / drug therapy
  • Fatty Liver / metabolism
  • Gene Expression
  • Insulin Resistance
  • Lignans / pharmacology*
  • Lignans / therapeutic use
  • Lipid Metabolism / drug effects*
  • Lipids / blood
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Obesity / blood
  • Obesity / etiology
  • Obesity / metabolism
  • Obesity / prevention & control
  • Picea / chemistry*
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use

Substances

  • Anti-Obesity Agents
  • Blood Glucose
  • Lignans
  • Lipids
  • Plant Extracts
  • hydroxymatairesinol
  • 2,3-bis(3'-hydroxybenzyl)butane-1,4-diol
  • 4-Butyrolactone
  • 2,3-bis(3'-hydroxybenzyl)butyrolactone